Search
Dostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigational[L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month. … [A234379] Agents acting on the PD-1 pathway, such as [nivolumab] and [pembrolizumab], facilitate endogenous immune-mediated anti-tumor activity and may therefore be used to treat a wide variety of cancers
Riluzole
go.drugbank.com/drugs/DB00740ApprovedInvestigationalA glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis.
Categories: Compounds used in a research, industrial, or household settingMethyclothiazide
go.drugbank.com/drugs/DB00232ApprovedWithdrawnA thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)
Categories: combinations of sulfonamidesMe-4(18F)DG
go.drugbank.com/drugs/DB19207InvestigationalMe-4(18F)DG is under investigation in clinical trial NCT05558904 (An Investigational Scan (Me-4fdg PET/CT) for the Detection of Sodium-glucose Transport for Early Diagnosis of Lung Cancer).
Synonyms: -d-glucopyranoside, methyl 4-deoxy-4-(fluoro-18f)-, -methyl-4-(F-18)-fluoro-4-deoxy-d-glucopyranosidePropylhexedrine
go.drugbank.com/drugs/DB06714ApprovedPropylhexedrine is an alpha-adrenergic agonist often used in nasal decongestant inhalers. It is used to give temporary relief for nasal congestion from colds, allergic rhinitis, or allergies.
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedApproved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [DB00811] depending on the the presence of resistance associated amino acid substitutions … The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself.
Categories: Antivirals for treatment of HCV infectionsVernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.
Synonyms: (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-olBenazepril
go.drugbank.com/drugs/DB00542ApprovedInvestigationalUpon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836].
Categories: Agents Acting on the Renin-Angiotensin SystemEtoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawnIt is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile. … Etoperidone is an atypical antidepressant introduced in Europe in 1977.
Categories: Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeYKP-1358
go.drugbank.com/drugs/DB06109ExperimentalYKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. … In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Dopamine D2 Receptor Antagonists